← Home
© 2024 - 2025 InsightfulValue.com. All rights reserved.
Press Releases
Date | Press release |
---|---|
2025-04-30 08:05:00 | Takeda Awards $13.8 Million To U.s. Nonprofit Partners To Promote Healthy Eating And Expand Stem Education Cambridge, mass.--(business wire)--takeda has awarded grants to seven nonprofits that share its commitment to creating better health for people and a brighter future for the world. |
2025-04-08 07:15:00 | Bioinvent Receives Milestone Payment As Takeda Moves Mezagitamab Into Phase 3 Lund, sweden / access newswire / april 8, 2025 / bioinvent international ab (\"bioinvent\") (nasdaq stockholm:binv), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that it has earned a 1 million usd milestone payment, following takeda’s (tse:4502/nyse:tak) initiation of phase 3 clinical trial of mezagitamab (tak-079), identified from bioinvent’s proprietary n-coder® antibody library. the study is evaluating this potential best-in-class anti-cd83 monoclonal antibody for persistent or chronic primary immune thrombocytopenia (itp). |
2025-03-03 06:45:00 | Protagonist And Takeda Announce Positive Topline Results From Phase 3 Verify Study Of Rusfertide In Patients With Polycythemia Vera Newark, calif. & osaka, japan & cambridge, mass.--(business wire)--protagonist therapeutics, inc. (“protagonist”) (nasdaq:ptgx) and takeda (tse:4502/nyse:tak) today announced positive topline results for the phase 3 verify study, in which phlebotomy-dependent patients with polycythemia vera (pv) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. the study met its primary endpoint and all four key secondary endpoints. rusfertide is a first. |
2025-02-24 03:01:00 | The European Medicines Agency (ema) Has Approved An Additional Subcutaneous Administration Option For Takhzyro® (lanadelumab) For Patients Aged 12 Years And Above With Recurrent Attacks Of Hereditary Angioedema (hae) Takhzyro solution for injection in 2 ml pre-filled pen is now approved to facilitate subcutaneous administration in adolescent (aged 12 years and above) and adult patients with hae.1 the pre-filled pen option is designed to allow for an individualized treatment approach for adolescent and adult hae patients. in the eu, takhzyro is approved for routine prevention of recurrent hae attacks in patients aged 2 years and older.1 zurich , feb. 24, 2025 /prnewswire/ -- takeda (tse: 4502) (nyse: tak) announced today that the ema has approved an additional 2 ml pre-filled pen option for takhzyro® (lanadelumab) for subcutaneous administration in adolescents (aged 12 years and above) and adult patients with hereditary angioedema (hae).1 the additional subcutaneous administration option expands takeda’s offering in this space, showing dedication to the hae community while providing individualized treatment options to support patients with a life-threatening disease, by helping to reduce hae burden and improving their quality of life. |
2025-01-30 09:00:00 | Suffolk Celebrates Topping Off For A Game-changing New Takeda Facility In Kendall Square Where Science, Art And Community Will Converge Boston--(business wire)--suffolk, one of the largest and most innovative real estate and construction enterprises in the country, recently celebrated topping off 585 kendall. designed by cbt architects, 585 kendall is a mixed-use lab/office building and performing arts center in the canal district of kendall square. the event recognized the construction teams that played a vital role in reaching this significant milestone. takeda has leased the property’s approximately 600,000-square-foot of la. |
2025-01-30 02:04:00 |
|
2025-01-30 01:35:00 |
|
2025-01-27 16:05:00 |
|
2024-12-27 01:00:00 |
|
2024-12-03 07:00:00 |
|
2024-11-20 11:30:00 |
|
2024-10-31 02:05:00 |
|
2024-09-26 08:30:00 |
|
2024-09-24 03:00:00 |
|
2024-09-18 10:00:00 |
|
